Magnesium Chloride
American Regent, Inc.

MAGNESIUM CHLORIDE INJECTION 200 mg/mL (20% w/v) 2.951 mOsmol/mL

MAGNESIUM CHLORIDE - magnesium chloride injection, solution 
American Regent, Inc.

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

MAGNESIUM CHLORIDE INJECTION
200 mg/mL (20% w/v)
2.951 mOsmol/mL

1

Rx Only

2DESCRIPTION

Magnesium Chloride Injection is a sterile solution of Magnesium Chloride Hexahydrate in Water for Injection q.s. Each mL contains: Magnesium Chloride Hexahydrate 200 mg, Sodium Chloride 9 mg, Benzyl Alcohol 1% as a preservative, Water for Injection, q.s. pH adjusted with Hydrochloric Acid and/or Sodium Hydroxide. Total osmolarity equivalent to 2951 mOsmol/L. Contains 1.97 mEq of Mg++ and Cl¯ per mL.

The structural formula is MgCl2•6H2O

3ACTIONS

Magnesium is the second most plentiful cation within cellular fluids. It is an important activator of many enzyme systems, and deficits are accompanied by a variety of functional disturbances.

4INDICATIONS AND USAGE

As an electrolyte replenisher in magnesium deficiencies.

5CONTRAINDICATIONS

Magnesium Chloride Injection should not be administered if there is renal impairment, marked myocardial disease or to comatose patients.

6WARNINGS

Do not use if a precipitate is present.

This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

7PRECAUTIONS

The usual precautions for parenteral administration should be observed.  Administer with caution if flushing and sweating occurs. A preparation of a calcium salt should be readily available for intravenous injection to counteract potential serious signs of magnesium intoxication. As long as deep tendon reflexes are active it is probable that the patient will not develop respiratory paralysis. Respiration and blood pressure should be carefully observed during and after administration of Magnesium Chloride Injection.

7.1Pregnancy

7.1.1Teratogenic Effects

Pregnancy Category C. Animal reproduction studies have not been conducted with magnesium chloride. It is also not known whether magnesium chloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Magnesium chloride should be given to a pregnant woman only if clearly needed.

8ADVERSE REACTIONS

Flushing, sweating, sharply lowered blood pressure, hypothermia, stupor, and ultimately respiratory depression.

9DOSAGE AND ADMINISTRATION

For intravenous infusion: 4 grams in 250 mL of 5% Dextrose Injection, at a rate not exceeding 3 mL per minute. Serum magnesium levels should serve as a guide to continued dosage.

USUAL DOSAGE RANGE: 1 to 40 grams daily.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

10HOW SUPPLIED

Magnesium Chloride Injection 200 mg/mL (20% w/v)

NDC 0517-5034-01     50 mL Multiple Dose Vial     Individually boxed

Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) (See USP Controlled Room Temperature).

AMERICAN
REGENT, INC.
SHIRLEY, NY 11967

IN5034

Rev. 1/09

11PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

PRINCIPAL DISPLAY PANEL – 50 mL Container

NDC 0517-5034-01

MAGNESIUM
CHLORIDE
INJECTION

200 mg/mL
(20% w/v)
2.951 mOsmol/mL

50 mL
MULTIPLE DOSE VIAL

Rx Only

AMERICAN REGENT, INC.
SHIRLEY, NY 11967

60f78290-figure-01
MAGNESIUM CHLORIDE 
magnesium chloride injection, solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0517-5034
Route of Administration INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
MAGNESIUM CHLORIDE (MAGNESIUM) MAGNESIUM CHLORIDE 200 mg  in 1 mL
Inactive Ingredients
Ingredient Name Strength
SODIUM CHLORIDE 9 mg  in 1 mL
BENZYL ALCOHOL  
HYDROCHLORIC ACID  
SODIUM HYDROXIDE  
WATER  
Packaging
# Item Code Package Description
1 NDC:0517-5034-01 1 in 1 CARTON
1 50 mL in 1 VIAL, MULTI-DOSE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
Unapproved drug other 09/30/1990
Labeler - American Regent, Inc. (622781813)

Revised: 10/2011
 
American Regent, Inc.

Pill Identification Tool